Summit Therapeutics (SMMT) said Friday that a phase 3 trial evaluating ivonescimab combined with platinum-doublet chemotherapy showed a "statistically significant benefit in overall survival" in patients with metastatic non-squamous non-small cell lung cancer.
The drug combination demonstrated a "clinically meaningful" improvement when compared with chemotherapy alone, the company said.
Shares of Summit Therapeutics were down 3.3% in recent trading.
Price: 17.95, Change: -0.50, Percent Change: -2.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments